| Day 1. May 29th |
| |
| 20.00-20.15 |
AstraZeneca Welcome address |
Agustín Espejo (CHI) |
| 20.15-20.25 |
Meeting objectives |
Vivencio Barrios (SPA) |
| 20.25-21.00 |
Cardiovascular risk management: latest evidence |
Allan Gaw (UK) |
| 21.00-22.30 |
Dinner |
All |
| |
| Day 2. May 30th |
| |
| 09.30-09.40 |
Introduction to the day |
Vivencio Barrios (SPA) &
Antonio Carlos P. Chagas (BRA) |
| 09.40-10.10 |
Justification for use of statins in prevention: an international trial evaluating rosuvastatin: JUPITER trial presentation and conclusions |
Francisco A.H. Fonseca (BRA) |
| 10.10-10.40 |
The real impact of high-sensitivity C-reactive protein levels reduction in clinical practice |
Alberto Lorenzatti (ARG) |
| 10.40-11.10 |
Statin therapies: strengths, limitations, and clinical considerations |
Allan Gaw (UK) |
| 11.10-11.40 |
Round table discussion: ask the panel |
Vivencio Barrios (SPA) |
| 11.40-12.10 |
BREAK |
|
| 12.10-12.40 |
Utility of ARBs II in the treatment of metabolic syndrome |
José Luis Cervantes (MEX) |
| 12.40-13.10 |
Cardiovascular continuum: the RASS perspective |
Daniel Pichel (PAN) |
| 13.10-13.40 |
Antihypertensive drugs in daily clinical practice: are there differences between genders? |
Oswaldo Kohlmann (BRA) |
| 13.40-14.10 |
Round table discussion: ask the panel |
Paola Varleta (CHI) |
| 14.10-14.30 |
Conclusions of the day |
Antonio Carlos P. Chagas (BRA)
|
| 14.30-15.30 |
Lunch |
|
| |
| Day 3. May 31st |
| |
| 09.30-09.40 |
Introduction to the day |
Vivencio Barrios (SPA) &
Antonio Carlos P. Chagas (BRA) |
| 09.40-10.10 |
Relationship between microalbuminuria and cardiovascular
events in patients with diabetes mellitus and hypertension |
Jaime Díaz (CHI) |
| 10.10-11.10 |
Workshop 1: Hypertension and heart failure: how to modify this relation |
Coordinator
Oswaldo Kohlmann (BRA) |
| |
Workshop 2: Atherosclerotic and CV diseases:
a new form of thinking in cardiovascular diseases |
Coordinator Daniel Pichel (PAN) |
| |
Workshop 3: New frontiers in a strategy for treatment of metabolic syndrome |
Coordinator
Alberto Lorenzatti (ARG) |
| |
Workshop 4: How to obtain the “Gold Standard” for treating mixed dyslipidemia |
Coordinator Paola Varleta (CHI) |
| |
Workshop 5: Selective B-blockers in cardiovascular diseases |
Coordinator Álvaro Ruiz (COL) |
| 11.10-11.40 |
BREAK |
|
| 11.40-12.20 |
The cause and prevention of atherosclerosis: what is the new thing? |
William Roberts (USA) |
| 12.20-13.00 |
New evidences of ARBs on microvascular damage |
Vivencio Barrios (SPA) |
| 13.00-13.30 |
Bioequivalence and bioavailability of drugs: role in the decision making process |
Álvaro Ruiz (COL) |
| 13.30-14.00 |
Round table discussion: ask the panel |
Antonio Carlos P. Chagas (BRA) |
| 14.00-14.20 |
Conclusions of the day & close |
Vivencio Barrios (SPA) &
Antonio Carlos P. Chagas (BRA) |
| 14.20-15.20 |
Lunch |
|
